Safety and Efficacy of COV795 in Moderate to Severe Post-Operative Bunionectomy Pain With an Open-label Extension

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

329 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to show the effectiveness of repeated doses of COV795 versus placebo, using the summed pain intensity difference over the first 48 hours in subjects with acute moderate to severe pain following bunionectomy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain

NCT01743625

Pain, Postoperative Bunion

COMPLETED PHASE3

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

NCT00656578

Pain

COMPLETED PHASE3

XG005 for Pain Control in Subjects Undergoing Bunionectomy

NCT06017999

Acute Pain

COMPLETED PHASE2/PHASE3

Analgesic Efficacy Of Valdecoxib In Patients Following Bunion Surgery

NCT00653354

Pain, Post-surgical

COMPLETED PHASE3

Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy

NCT03997812

Pain, Postoperative

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative Bunion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

COV795

Group Type EXPERIMENTAL

COV795

Intervention Type DRUG

2 tablets taken every 12 hours

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

2 tablets taken every 12 hours

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

COV795

2 tablets taken every 12 hours

Intervention Type DRUG

Placebo

2 tablets taken every 12 hours

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MNK795

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Complete the informed consent process as documented by signed informed consent form(s).
2. Be in generally good health.
3. Be 18 to 75 years of age, inclusively at the time of screening.
4. Be scheduled for a primary unilateral first metatarsal bunionectomy (with no collateral procedures).
5. Have a body mass index ≤33 kg/m2.
6. Female subjects are eligible only if not pregnant, not lactating, not planning to become pregnant for the duration of the study, surgically sterile or at least two years postmenopausal, or practicing an acceptable form of birth control for at least 2 months
7. Male subjects must be sterile or commit to the use of a reliable method of birth control
8. Be classified as Physical status 1 (PS-1) to PS-2 by the American Society of Anesthetists (ASA) Physical Status Classification System.
9. Be willing to complete the pain evaluations and return to the clinic as scheduled.

Exclusion Criteria

1. Have an uncontrolled medical condition, serious intercurrent illness, clinically significant general health condition, or extenuating circumstance that may significantly decrease study compliance or otherwise preclude their participation in the study.
2. Have a clinically significant abnormal electrocardiogram (ECG) at screening
3. Have had any type of gastric bypass surgery or have a gastric band.
4. Have previous abdominal surgery within the past year or history of abdominal adhesions, known or suspected paralytic ileus.
5. Have a history of any medical condition that would alter the absorption, distribution, metabolism or excretion of COV795
6. Have a history of severe bronchial asthma, hypercarbia, or hypoxia
7. Have a clinically significant abnormality on their clinical laboratory values
8. Have Addison's disease, benign prostatic hyperplasia, or kidney disease
9. Have donated blood or blood components within 3 months prior to the screening visit.
10. Have a known allergy or hypersensitivity to any opioid analgesics, anesthetics, acetaminophen, Non-steroid anti-inflammatory drugs (NSAIDs).
11. Have a history of intolerance to short term opioid use.
12. Unwilling to discontinue certain prohibited medications within the allotted time before surgery and throughout the duration of the study. Have taken certain drugs within the indicated times before surgery.
13. Have a history of substance or alcohol abuse and/or a positive result on drug screening.
14. Have a positive test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at the screening visit.
15. Have dysphagia and/or cannot swallow study medication whole.
16. Have a history of migraine or frequent headaches, seizures, or are currently taking anticonvulsants.
17. Have previously participated in a clinical trial using COV795 or had a bunionectomy in the last 3 months.
18. Received any investigational drugs or devices within 4 weeks prior to the screening visit.
19. Other criteria as specified in the trial protocol.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No